Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253603 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetics of QAW039
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01253603: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01253603 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253603, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
Interventions
- DRUG QAW039 capsules once daily for 28 days
- DRUG Placebo to QAW039 capsules once daily for 28 days
- DRUG Fluticasone propionate inhaler twice daily for 28 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01253603 record still lists
NCT01253603 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 3 interventions - of which QAW039 capsules once daily for 28 days is the first listed.
NCT01253603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01253603 about?
NCT01253603 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of QAW039". This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
What is the current status of trial NCT01253603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01253603?
The interventions under investigation include: QAW039 capsules once daily for 28 days (DRUG), Placebo to QAW039 capsules once daily for 28 days (DRUG), Fluticasone propionate inhaler twice daily for 28 days (DRUG).
Who is sponsoring clinical trial NCT01253603?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01253603's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia